Philippe Monteyne
Partner @ Fund+
Brussels, Belgium
Philippe Monteyne is a Series A investor at Fund+ in Brussels focused on Biotechnology and Health Care. Philippe MONTEYNE holds an M.D. degree trained as a Neurologist and a Ph.D. in Viral Immunology, both at the UCL (Univ. Cathol. de Louvain), followed by a post-doctoral fellowship at Pasteur Institute, Paris. During the last 20 years, he held senior positions in top pharma companies such as SmithKline Beecham, GSK Biologicals (as Head of GlobalVaccine Development) and GSK Rare Diseases (Head of Development and Chief Medical Officer) and SANOFI (Vice President R&D France). He is also currently member of different Strategic Advisory Committees. He is also visiting Professor of Neurology at the UCL.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 40%
Last updated:
For AI agents: llms.txt
Industries Philippe Monteyne invests in
Stages Philippe Monteyne invests in
Countries Philippe Monteyne invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 4 (80%)
- Health Care 3 (60%)
- Genetics 2 (40%)
- Life Science 2 (40%)
- Therapeutics 2 (40%)
Stage
- Series A 2 (40%)
- Series B 2 (40%)
- Series C 1 (20%)
Country
- France 2 (40%)
- Spain 1 (20%)
- Belgium 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Minoryx, they are committed to finding innovative treatments for life threatening rare diseases. They focus on pediatric diseases and they are currently working on treatments for neurometabolic diseases of genetic origin.Minoryx develops a new generation of small molecule drugs known as pharmacological chaperones, which offer the most promisingapproach to the treatment of genetic diseases severely affecting the central nervous system. As a complementary approach, Minoryx is also involved in repositioning-based projects. | $54.7M / Series C / May 31, 2022 | ||
| Egle Therapeutics is an emerging biotechnology company focused on developing First-In-Class immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases. The company was founded in 2020 and is based in Paris, France. | $46.6M / Series A / Oct 22, 2021 | ||
| ExeVir Bio is a Belgium-based company that develops single-domain antibody-based therapies that help patients ward off viral infections. The company is harnessing a llama-derived antibody technology platform to generate robust antiviral therapies providing broad protection against coronaviruses. They using a highly innovative and clinicallyvalidated VHH technology to develop treatments for viral infections that may pose a significant global threat. ExeVir Bio develops a rapid response platform for antivirals. This platform technology enables an agile response to new health threats thanks to its short throughput time to generate drug candidates. The resulting protein-based therapeutics are sufficiently stable and easy to produce at a reasonable cost to enable true global access.ExeVir Bio was founded in 2020 and is headquartered in Zwijnaarde, Belgium. | $49.2M / Series A / Jul 28, 2020 | ||
| Minoryx, they are committed to finding innovative treatments for life threatening rare diseases. They focus on pediatric diseases and they are currently working on treatments for neurometabolic diseases of genetic origin.Minoryx develops a new generation of small molecule drugs known as pharmacological chaperones, which offer the most promisingapproach to the treatment of genetic diseases severely affecting the central nervous system. As a complementary approach, Minoryx is also involved in repositioning-based projects. | $25M / Series B / Sep 26, 2018 | ||
| Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases. | $22M / Series B / Nov 08, 2017 |
Co-Investors
About Fund+
Fund+ is a venture capital firm that invests in companies operating in the diagnostics, therapeutics, medical devices, and life science sectors. The firm wants to create sustainable shareholders' value, contribute to the development of a leadership position in the life sciences sector, and generate a tangible, beneficial societal impact.
Fund+ Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Desire Collen
Founder & Chairman
|
|||
|
Philippe Monteyne
Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Philippe Monteyne invest in?
Philippe Monteyne invests primarily in Biotechnology, Health Care and Genetics startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Philippe Monteyne?
Public channels for Philippe Monteyne include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Philippe Monteyne last invest?
The most recent investment recorded for Philippe Monteyne closed in May 2022. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
